Meta-analyses of gene methylation and smoking behavior in non-small cell lung cancer patients

Huang, Tao; Chen, Xiaoying; Hong, Qingxiao; Deng, Zaichun; Ma, Hongying; Xin, Yanfei; Fang, Yong; Ye, Huadan; Wang, Rujie; Zhang, Cheng; Meng, Yijun; Duan, Shiwei

doi:10.1038/srep08897

Cited by 62 publications

(55 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various human cancers are characterized by the functional loss of the INK4a family of proteins and the over expression of p16INK4a. Such factors are significantly associated with the outcome of many malignant tumors such as cervical cancer, osteosarcoma, gastrointestinal stromal tumor, head and neck squamous cell carcinoma, and non-small lung cancer (Zong et al, 2012;Bu et al, 2014;Huang et al, 2014;Ndiaye et al, 2014;Huang et al, 2015). There remains a scarcity of published evidence to support the role of over expressed p16INK4a in USMTs.…”

Section: Discussionmentioning

confidence: 95%

Is differential expression of p16INK4a based on the classification of uterine smooth muscle tumors associated with a different prognosis? A meta-analysis

et al. 2017

View full text Add to dashboard Cite

ABSTRACT. We conducted a meta-analysis to examine p16INK4a expression in uterine smooth muscle tumors (USMTs). Although the prognostic value of tumor suppressor p16INK4a has been elucidated in a variety of cancers and precancerous lesions, its role in USMTs is not well established. We searched PubMed, Web of Science, and Embase for publication son p16INK4a expression in USMTs. Strict inclusion and exclusion criteria were imposed. Risk ratios (RRs) with 95% confidence intervals (95%CIs) were calculated to assess the strength of association. Publication bias was estimated using funnel plots and the Egger's regression test. Twelve eligible studies comprising 661 patients were included. Compared with leiomyoma (LM), the figures for the strength of association were as follows: LM variants (RR = 1.53, 95%CI = 1.03-2.27, P = 0.036, random effect); leiomyosarcoma (LMS) (RR = 3.20, 95%CI = 1.68-6.12, P < 0.001, random effect); and smooth muscle tumors of uncertain malignant potential (STUMP) (RR = 2.90, 95%CI = 1.17-7.21, P = 0.022, random effect). p16INK4a expression was significantly higher in LMS than in LM variants (RR = 3.74, 95%CI = 1.96-7.13, P < 0.001, random effect) or STUMP (RR = 1.67, 95%CI = 1.26-2.23, P < 0.001, fixed effect). There was a significant correlation between overexpressed p16INK4a and recurrence rates of USMTs (RR = 1.85, 95%CI = 1.11-3.10, P = 0.019, fixed effect). p16INK4a over expression is a potential biomarker for diagnosing problematic USMTs and it might indicate a worse prognosis. However, there is currently insufficient evidence to assess the prognostic value of p16INK4a in USMTs.

show abstract

Section: Discussionmentioning

confidence: 95%

Is differential expression of p16INK4a based on the classification of uterine smooth muscle tumors associated with a different prognosis? A meta-analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…These mechanisms often seem to have a different course in cancer cells than in normal human cells (48). It has been recently proven that in cases of non-small cell lung cancer (NSCLC) there is a high heterogeneity of the methylation process (49,50). For example, non-malignant lung tissue (NMLT) is characterized by a high level of methylation of the SOX18 gene promoter.…”

Section: Non-small Cell Lung Cancermentioning

confidence: 99%

Role of the SOX18 protein in neoplastic processes (Review)

2018

View full text Add to dashboard Cite

Abstract. There is a high demand for anticancer drugs due to the fact that the chemotherapeutics currently used have numerous side effects, which lowers the patient's quality of life. However, the latest antibody therapies are extremely expensive, hence the requirement to identify novel, equally effective but low-toxic treatments that have limited side effects. As a result of this, a number of research centres around the world are attempting to identify novel molecular markers that could be effective targets for anticancer therapy in the future. The SOX18 protein has been suggested to be a significant diagnostic and prognostic marker in various types of cancer. SRY-related HMG-box 18 (SOX18) is an important transcription factor involved in the development of cardiovascular and lymphatic vessels during embryonic development. In addition, it is involved in the progression of atherosclerosis and wound-healing processes. It has been observed that its level is higher in a number of cancer types, including melanoma, pancreas, stomach, liver, breast, lung, ovarian and cervical cancer. Furthermore, an association between a high expression of SOX18 in gastric cancer stromal cells and a poor prognosis has been demonstrated. The literature indicates how complex the pathogenesis of cancer is. Knowing the molecular basis of the pathogenesis of the tumor will allow for the effective use of targeted therapy, which may result in a higher success in treating patients. It is therefore important to identify novel and effective therapies as well as new proteins that could be potential markers. The SOX18 family, represented by the SOX18 protein, seems to be in this respect a promising element in modern anticancer therapy.

show abstract

“…Epigenetic silencing of tumor suppressor genes by promoter hyper methylation is considered to be a significant event in the progression of cancers including leukemia (7), lung cancer (8) and prostate cancer (9). Gene-body methylation levels are also demonstrated to be correlated with gene expression (10,11).…”

Section: Introductionmentioning

confidence: 99%

TGFB2 and BCL2L11 methylation in male laryngeal cancer patients

Shen

Chen

et al. 2016

Oncology Letters

Self Cite

View full text Add to dashboard Cite

Abstract. DNA methylation is a major regulatory mechanism of gene expression. The aim of the present study was to test the association of transforming growth factor β2 (TGFB2) and B cell lymphoma 2-like 11 (BCL2L11) gene methylation with the risk of laryngeal squamous cell carcinoma (LSCC). Using bisulfite pyrosequencing technology, DNA methylation levels of TGFB2 promoter and BCL2L11 gene-body CpG cytosines were measured in 90 LSCC tissues and 90 adjacent normal tissues. Analysis of variance and paired sample t-test were used to determine the association of gene methylation and the risk of LSCC. Our results revealed that there were no differences in TGFB2 and BCL2L11 methylation levels between the LSCC tissues and the paired normal tissues (P>0.05). Further breakdown analyses demonstrated that the association results of the two gene methylation levels and LSCC remained unchanged with the age, smoking history, histological differentiation or clinical stage of the LSCC patients (all adjusted P>0.05). In conclusion, there is no association of TGFB2 promoter and BCL2L11 gene-body methylation with the risk of LSCC in males. IntroductionLaryngeal squamous cell carcinoma (LSCC) is the second most common head and neck cancer in the world (1). The incidence of LSCC in China has exhibited an increasing trend in the young population (2,3). LSCC is a complex disease, and it is hypothesized that both genetic and environmental factors play a role in it (4). Epigenetic modifications, including DNA methylation, are known as the bridging factors of genetics and the environment (5). However, the role of epigenetic modifications in the pathogenesis and progression of LSCC remains to be explained.DNA methylation of CpG islands (CGIs) is a significant regulatory mechanism of gene expression (6). Epigenetic silencing of tumor suppressor genes by promoter hyper methylation is considered to be a significant event in the progression of cancers including leukemia (7), lung cancer (8) and prostate cancer (9). Gene-body methylation levels are also demonstrated to be correlated with gene expression (10,11).TGFB2 is a member of the transforming growth factor β (TGFB) family, which encodes multifunctional peptides in the regulation of cell proliferation, differentiation, adhesion and migration (12). TGFB is able to inhibit tumor growth at the early stages and promote tumor growth at the late stages of disease (13). A previous study has demonstrated that increased TGFB2 promoter methylation level is associated with prostate cancer progression (14). BCL2L11 encodes a member of the BCL-2 (B cell lymphoma 2) protein family, which acts as an apoptotic activator that is involved in a wide variety of cellular activities (15). BCL2L11 methylation has been noted to be associated with the risk of hematological and epithelial cancers (16).In the current study, the methylation levels of TGFB2 and BCL2L11 were investigated in male laryngeal cancer patients to determine whether these epigenetic markers are associated with LSCC risk. Materials and methods

show abstract

Meta-analyses of gene methylation and smoking behavior in non-small cell lung cancer patients

Cited by 62 publications

References 36 publications

Is differential expression of p16INK4a based on the classification of uterine smooth muscle tumors associated with a different prognosis? A meta-analysis

Is differential expression of p16INK4a based on the classification of uterine smooth muscle tumors associated with a different prognosis? A meta-analysis

Role of the SOX18 protein in neoplastic processes (Review)

TGFB2 and BCL2L11 methylation in male laryngeal cancer patients

Contact Info

Product

Resources

About